Enanta Pharmaceuticals, Inc. (ENTA) — QMA analysis
Sector: Healthcare · Market cap: $292M · Price: $11,62 · Data as of 2026-10-22
Enanta Pharmaceuticals, Inc. has a below-average composite score of 34/100, higher score than 12% of 22,733 tracked stocks. The highest-scoring layer is Analysts / transcripts; the lowest is Earnings quality.
What 10 data layers say about ENTA
The composite fuses insiders, congressional trades, institutional 13F positions, fundamentals, momentum, seasonality and more into a single number.
| Layer | Score |
|---|---|
| Fundamental value (FVS) | 30/100 |
| Earnings quality (EQS) | 20/100 |
| Technical trend (TSS) | 43/100 |
| Relative strength (RS) | 26/100 |
| Momentum (USS) | 40/100 |
| Insider activity (IAS) | 21/100 |
| Off-exchange trading (FINRA) / large flows (WHS) | 32/100 |
| News sentiment (NSS) | 52/100 |
| Analysts / transcripts (ATS) | 84/100 |
| Catalysts (XS) | 35/100 |
What does the QMA model currently show for Enanta Pharmaceuticals, Inc.?
The composite score is a research starting point, not an instruction. What matters is layer confluence — whether the layers point in the same direction.
For ENTA the layers diverge — some score high (Analysts / transcripts), others low (Earnings quality). The divergence is itself information: the model does not give a clear-cut picture. The score is an input into your own research, not a recommendation.
ENTA insider & smart money activity
Over the recent period we record 6 reported insider purchases and 0 sales for ENTA: only reported purchases, no sales. A description of the data layer, not an instruction.
How ENTA compares
Similar stocks from the same sector:
Frequently asked questions
What is the composite score for ENTA stock?
34/100 (F) — Data as of 2026-10-22.
Are insiders buying ENTA stock?
Over the recent period, reported: purchases 6, sales 0 (purchases $1.7M). Insider activity: only reported purchases, no sales — a description of reported data, not a trade instruction.
Where can I see live ENTA data?
Live ENTA data and the full screener are part of full access. Registration is free with no card — trial full access, then the free plan with a delayed data sample.
Data from SEC and public markets. QMA is an analytical tool, not a registered investment advisor. No content on this page is investment advice or an instruction to buy or sell. Past performance does not guarantee future results.
⚠️ Important Notice: QMA is an analytical and educational tool, not investment advice. Scores, detections and ratings are descriptive, not buy/sell instructions. QMA is not a registered investment advisor (SEC / FINRA / MiFID II / ČNB). Consult a licensed financial advisor before any investment. Past performance does not guarantee future results; all investments carry the risk of capital loss.
Operator: Jaroslav Vojtášek · IČO: 48783447 · Place of business: U Jízdárny 577, 747 64 Velká Polom, Czech Republic · Register: Sole trader registered in the Czech Trade Licensing Register · E-mail: [email protected]